The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
Lip
Gregory Y H
GY
D000925:Anticoagulants / Q000009:adverse effects* / Q000592:standards; D001241:Aspirin / Q000009:adverse effects / Q000592:standards; D001281:Atrial Fibrillation / Q000453:epidemiology* / Q000503:physiopathology; D001779:Blood Coagulation Factors / Q000032:analysis; D002545:Brain Ischemia / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000503:physiopathology; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015897:Comorbidity; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000592:standards / Q000627:therapeutic use; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D014859:Warfarin / Q000009:adverse effects / Q000592:standards
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin